RMAT designation expected to expedite development; 72 weeks interim clinical trial data showing sus...
SUZHOU, China, May 12, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its three a...
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its in...
SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Accuredit Therapeutics (Suzhou) Co., Ltd. (hereinafter...
